Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 1:30 AM ET

Date/Time Source News Release
09/03/2024 10:15 AM EDT Newsfile Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
07/31/2024 06:30 PM EDT Newsfile Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
07/16/2024 07:15 AM EDT Newsfile Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
05/28/2024 05:00 PM EDT Newsfile Resverlogix Announces Updated Annual and Special Meeting of Shareholders
05/13/2024 05:00 PM EDT Newsfile Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
02/21/2024 07:00 PM EST Newsfile Resverlogix Announces Change to Its Board of Directors
01/11/2024 07:15 AM EST Newsfile Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
10/04/2023 07:12 AM EDT Newsfile Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
08/29/2023 07:15 AM EDT Newsfile Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
06/29/2023 06:00 PM EDT Newsfile Resverlogix Announces Warrant Repricing and One-Year Extension
Page